Literature DB >> 8911359

Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.

E T Fernandes1, J C Manivel, P K Reddy, C J Ercole.   

Abstract

PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.
MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.
RESULTS: All tumors were grade 3 or 4 transitional cell carcinoma. Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease. Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months. The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later.
CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease. However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911359

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Accuracy and Readability of Websites on Kidney and Bladder Cancers.

Authors:  Samy A Azer; Maha M Alghofaili; Rana M Alsultan; Najla S Alrumaih
Journal:  J Cancer Educ       Date:  2018-08       Impact factor: 2.037

3.  Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma.

Authors:  Bjoern G Volkmer; Evelyn M Seidl-Schlick; Dietmar Bach; Imre Romics; Klaus Kleinschmidt
Journal:  Clin Rheumatol       Date:  2004-12-01       Impact factor: 2.980

Review 4.  Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.

Authors:  A Knight; J Askling; F Granath; P Sparen; A Ekbom
Journal:  Ann Rheum Dis       Date:  2004-05-06       Impact factor: 19.103

5.  [The causes of urinary bladder cancer and possibilities of prevention].

Authors:  K Golka; A W Rettenmeier; P J Goebell
Journal:  Urologe A       Date:  2006-03       Impact factor: 0.639

6.  Pathobiology and chemoprevention of bladder cancer.

Authors:  Takuji Tanaka; Katsuhito Miyazawa; Tetsuya Tsukamoto; Toshiya Kuno; Koji Suzuki
Journal:  J Oncol       Date:  2011-09-15       Impact factor: 4.375

7.  Repeated Low-Dose Acrolein Triggers Irreversible Lamina Propria Edema in Urinary Bladder, Transient Voiding Behavior and Widening of Eyes to Mechanical Stimuli.

Authors:  Sanghee Lee; Jiwoo Lee; Chandresh Khimji; Jaebeom Lee; Shelle Malkmus; Michael Albo; Tony Yaksh; George Chiang
Journal:  Cells       Date:  2021-12-09       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.